Anke L. Stuurman
About
Anke L. Stuurman is a scholar working on Epidemiology, Health and Infectious Diseases.
According to data from OpenAlex, Anke L. Stuurman has authored 26 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Epidemiology, 13 papers in Health and 11 papers in Infectious Diseases. Recurrent topics in Anke L. Stuurman's work include Influenza Virus Research Studies (14 papers), Vaccine Coverage and Hesitancy (13 papers) and SARS-CoV-2 and COVID-19 Research (7 papers). Anke L. Stuurman is often cited by papers focused on Influenza Virus Research Studies (14 papers), Vaccine Coverage and Hesitancy (13 papers) and SARS-CoV-2 and COVID-19 Research (7 papers). Anke L. Stuurman collaborates with scholars based in Belgium, United Kingdom and France. Anke L. Stuurman's co-authors include Russell J. Brooke, Karen L. Peterson, Mirjam Kretzschmar, Cheryl Gibbons, Dietrich Plaß, Piotr Kramarz, Marie‐Josée J. Mangen, Alessandro Cassini, Eric M. Fèvre and Arie H. Havelaar and has published in prestigious journals such as PLoS ONE, International Journal of Environmental Research and Public Health and BMC Public Health.
In The Last Decade
Anke L. Stuurman
25 papers receiving 614 citations
Peers
Anke L. Stuurman
Kayoko Shioda United States
Marc Rondy United States
Barrack Aura Kenya
Abdirahman Mahamud United States
Zack Moore United States
Ian D. Plumb United States
Karl Schenkel Germany
Graham Tallis Australia
Lorna Willocks United Kingdom
Paul Armstrong Australia
Citations per year, relative to Anke L. Stuurman Anke L. Stuurman (= 1×)
peers
Kayoko Shioda
Countries citing papers authored by Anke L. Stuurman
Since
Specialization
Citations
This map shows the geographic impact of Anke L. Stuurman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anke L. Stuurman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anke L. Stuurman more than expected).
Fields of papers citing papers by Anke L. Stuurman
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Anke L. Stuurman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anke L. Stuurman. The network helps show where Anke L. Stuurman may publish in the future.
Co-authorship network of co-authors of Anke L. Stuurman
This figure shows the co-authorship network connecting the top 25 collaborators of Anke L. Stuurman. A scholar is included among the top collaborators of Anke L. Stuurman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anke L. Stuurman. Anke L. Stuurman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Stuurman, Anke L., et al.. (2025). Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis. Expert Review of Vaccines. 24(1). 703–725.
2.
Stuurman, Anke L., et al.. (2025). Real-world Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children and Adolescents from 2003 to 2023: a Plain Language Summary of Publication. Therapeutic Advances in Infectious Disease. 12. 2038625496–2038625496.
3.
Meeraus, Wilhelmine, Anke L. Stuurman, Eduardo Conde‐Sousa, et al.. (2023). COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron. Vaccine. 41(42). 6366–6378.
4.
Stuurman, Anke L., Jorne Lionel Biccler, Miriam Levi, et al.. (2023). Brand-specific estimates of influenza vaccine effectiveness for the 2021–2022 season in Europe: results from the DRIVE multi-stakeholder study platform. Frontiers in Public Health. 11. 1195409–1195409.
5.
Meeraus, Wilhelmine, Leonie de Munter, Christen M. Gray, et al.. (2023). Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis. The Lancet Regional Health - Europe. 31. 100675–100675.
6.
Stuurman, Anke L., Margarita Riera-Montes, Neeraj Kashyap, et al.. (2022). Estimating baseline rates of adverse perinatal and neonatal outcomes using a facility-based surveillance approach: A prospective observational study from the WHO Global Vaccine Safety Multi-Country Collaboration on safety in pregnancy. EClinicalMedicine. 50. 101506–101506.
7.
Stuurman, Anke L., Margarita Riera-Montes, Neeraj Kashyap, et al.. (2022). Operational lessons learned in conducting an international study on pharmacovigilance in pregnancy in resource-constrained settings: The WHO Global Vaccine safety Multi-Country collaboration project. Vaccine X. 11. 100160–100160.
8.
Stuurman, Anke L., Miriam Levi, Philippe Beutels, et al.. (2022). Investigating confounding in network‐based test‐negative design influenza vaccine effectiveness studies—Experience from the DRIVE project. Influenza and Other Respiratory Viruses. 17(1). e13087–e13087.
9.
Stuurman, Anke L., Jorne Lionel Biccler, Javier Díez‐Domingo, et al.. (2021). Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe – Results from the DRIVE EU study platform. Vaccine. 39(29). 3964–3973.
10.
Stuurman, Anke L., Margarita Riera-Montes, Neeraj Kashyap, et al.. (2021). WHO global vaccine safety multi-country collaboration project on safety in pregnancy: Assessing the level of diagnostic certainty using standardized case definitions for perinatal and neonatal outcomes and maternal immunization. Vaccine X. 9. 100123–100123.
11.
Stuurman, Anke L., Alfredo Vannacci, Antonino Bella, et al.. (2021). Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK. PLoS ONE. 16(6). e0252836–e0252836.
12.
Stuurman, Anke L., Kaatje Bollaerts, Jorne Lionel Biccler, et al.. (2020). Vaccine effectiveness against laboratory-confirmed influenza in Europe – Results from the DRIVE network during season 2018/19. Vaccine. 38(41). 6455–6463.
13.
Ferreira, Germano, Anke L. Stuurman, Yves Horsmans, et al.. (2019). Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink. European Journal of Gastroenterology & Hepatology. 32(1). 101–109.
14.
Stuurman, Anke L., Margarita Riera-Montes, Silvia Pérez-Vilar, et al.. (2018). Vaccine safety surveillance in pregnancy in low- and middle-income countries using GAIA case definitions: A feasibility assessment. Vaccine. 36(45). 6736–6743.
15.
Htar, Myint Tin Tin, Anke L. Stuurman, Germano Ferreira, et al.. (2017). Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS ONE. 12(5). e0177985–e0177985.
16.
Stuurman, Anke L., Marije Vonk Noordegraaf‐Schouten, Femke van Kessel, et al.. (2016). Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review. BMC Infectious Diseases. 16(1). 257–257.
17.
Sandgren, Andreas, Marije Vonk Noordegraaf‐Schouten, Femke van Kessel, et al.. (2016). Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infectious Diseases. 16(1). 204–204.
18.
Stuurman, Anke L., Cinzia Marano, Eveline M. Bunge, Laurence De Moerlooze, & Daniel Shouval. (2016). Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – A systematic review. Human Vaccines & Immunotherapeutics. 13(3). 724–736.
19.
Willame, Corinne, Dominique Rosillon, Anke L. Stuurman, et al.. (2016). Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Human Vaccines & Immunotherapeutics. 12(11). 2862–2871.
20.
Gibbons, Cheryl, Marie‐Josée J. Mangen, Dietrich Plaß, et al.. (2014). Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. BMC Public Health. 14(1). 147–147.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kayoko Shioda Breakdown of academic impact, for papers by Marc Rondy Breakdown of academic impact, for papers by Barrack Aura Breakdown of academic impact, for papers by Abdirahman Mahamud Breakdown of academic impact, for papers by Zack Moore Breakdown of academic impact, for papers by Ian D. Plumb Breakdown of academic impact, for papers by Karl Schenkel Breakdown of academic impact, for papers by Graham Tallis Breakdown of academic impact, for papers by Lorna Willocks Breakdown of academic impact, for papers by Paul Armstrong